 Mary Tobin
Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Food Hypersensitivity | 9 | 2017 | 30 | 1.450 |
Why?
| | Anaphylaxis | 3 | 2015 | 8 | 1.450 |
Why?
| | Immunity, Innate | 2 | 2015 | 68 | 1.110 |
Why?
| | Asthma | 6 | 2018 | 136 | 0.840 |
Why?
| | Sinusitis | 5 | 2018 | 142 | 0.830 |
Why?
| | Irritable Bowel Syndrome | 2 | 2008 | 42 | 0.800 |
Why?
| | Child Day Care Centers | 2 | 2006 | 5 | 0.740 |
Why?
| | Epinephrine | 2 | 2006 | 28 | 0.730 |
Why?
| | Desensitization, Immunologic | 1 | 2015 | 5 | 0.710 |
Why?
| | Rhinitis | 4 | 2018 | 118 | 0.680 |
Why?
| | Renal Dialysis | 1 | 2015 | 97 | 0.650 |
Why?
| | Kidney Failure, Chronic | 1 | 2015 | 158 | 0.600 |
Why?
| | Mast Cells | 2 | 2008 | 44 | 0.520 |
Why?
| | Hypersensitivity | 1 | 2008 | 41 | 0.410 |
Why?
| | Rhinitis, Allergic | 2 | 2018 | 17 | 0.400 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2004 | 9 | 0.340 |
Why?
| | Peroxidase | 1 | 2004 | 18 | 0.340 |
Why?
| | Hemorrhage | 1 | 2004 | 67 | 0.330 |
Why?
| | Vasculitis | 1 | 2004 | 34 | 0.330 |
Why?
| | Infant, Premature, Diseases | 1 | 2004 | 23 | 0.330 |
Why?
| | Lung Diseases | 1 | 2004 | 45 | 0.330 |
Why?
| | Leukocytes, Mononuclear | 2 | 2014 | 78 | 0.330 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2006 | 201 | 0.330 |
Why?
| | Dermatitis, Atopic | 2 | 2017 | 8 | 0.310 |
Why?
| | Kidney Diseases | 1 | 2004 | 133 | 0.290 |
Why?
| | Humans | 20 | 2018 | 25965 | 0.280 |
Why?
| | Digestive System | 1 | 2002 | 19 | 0.280 |
Why?
| | Celiac Disease | 1 | 2002 | 11 | 0.280 |
Why?
| | Pancreatitis | 1 | 2002 | 27 | 0.280 |
Why?
| | Infant | 5 | 2017 | 573 | 0.280 |
Why?
| | Crohn Disease | 1 | 2002 | 42 | 0.280 |
Why?
| | Female | 16 | 2018 | 15436 | 0.270 |
Why?
| | Adult | 11 | 2018 | 8507 | 0.260 |
Why?
| | Microbiota | 2 | 2018 | 82 | 0.250 |
Why?
| | Maternal-Fetal Exchange | 2 | 2013 | 12 | 0.240 |
Why?
| | Child, Preschool | 4 | 2017 | 727 | 0.230 |
Why?
| | Chronic Disease | 6 | 2018 | 466 | 0.230 |
Why?
| | Rhinitis, Allergic, Seasonal | 2 | 2008 | 7 | 0.220 |
Why?
| | Intestinal Mucosa | 2 | 2014 | 219 | 0.220 |
Why?
| | Nose | 1 | 2018 | 26 | 0.210 |
Why?
| | Child | 4 | 2018 | 1340 | 0.200 |
Why?
| | Dietary Fiber | 1 | 2017 | 24 | 0.200 |
Why?
| | Pollen | 1 | 2016 | 3 | 0.200 |
Why?
| | Male | 14 | 2018 | 15074 | 0.200 |
Why?
| | Eosinophilic Esophagitis | 1 | 2016 | 6 | 0.190 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2017 | 56 | 0.190 |
Why?
| | Minority Groups | 1 | 2016 | 61 | 0.190 |
Why?
| | Healthcare Disparities | 1 | 2016 | 52 | 0.190 |
Why?
| | Patient Acceptance of Health Care | 1 | 2016 | 55 | 0.190 |
Why?
| | Gastroesophageal Reflux | 1 | 2016 | 34 | 0.180 |
Why?
| | Skin Tests | 1 | 2015 | 17 | 0.180 |
Why?
| | Nasal Polyps | 1 | 2016 | 48 | 0.170 |
Why?
| | Granulocytes | 1 | 2014 | 25 | 0.170 |
Why?
| | Hispanic Americans | 1 | 2016 | 168 | 0.170 |
Why?
| | Toll-Like Receptors | 1 | 2014 | 26 | 0.170 |
Why?
| | Epithelial Cells | 1 | 2014 | 95 | 0.160 |
Why?
| | Middle Aged | 9 | 2018 | 9757 | 0.150 |
Why?
| | Hematologic Diseases | 1 | 2013 | 19 | 0.150 |
Why?
| | African Americans | 2 | 2016 | 618 | 0.150 |
Why?
| | Hospitalization | 1 | 2016 | 264 | 0.150 |
Why?
| | B-Lymphocytes | 1 | 2013 | 89 | 0.150 |
Why?
| | Infant, Newborn | 3 | 2016 | 630 | 0.150 |
Why?
| | Adolescent | 4 | 2018 | 2320 | 0.140 |
Why?
| | European Continental Ancestry Group | 1 | 2016 | 516 | 0.140 |
Why?
| | Odds Ratio | 2 | 2016 | 282 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 365 | 0.120 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 291 | 0.120 |
Why?
| | Receptors, IgE | 1 | 2009 | 2 | 0.120 |
Why?
| | Immunoglobulin E | 1 | 2009 | 16 | 0.120 |
Why?
| | Pregnancy | 2 | 2013 | 367 | 0.110 |
Why?
| | Dermatitis, Allergic Contact | 1 | 2008 | 7 | 0.110 |
Why?
| | Neutrophils | 1 | 2009 | 127 | 0.110 |
Why?
| | Aged | 5 | 2016 | 8589 | 0.100 |
Why?
| | Risk Factors | 2 | 2017 | 2222 | 0.090 |
Why?
| | Health Education | 1 | 2006 | 46 | 0.090 |
Why?
| | Mastocytosis, Systemic | 1 | 2006 | 4 | 0.090 |
Why?
| | Enterocolitis | 1 | 2006 | 5 | 0.090 |
Why?
| | Data Collection | 1 | 2006 | 119 | 0.090 |
Why?
| | Cytokines | 1 | 2008 | 335 | 0.090 |
Why?
| | Diarrhea | 1 | 2006 | 59 | 0.090 |
Why?
| | Illinois | 2 | 2017 | 215 | 0.090 |
Why?
| | Injections, Intramuscular | 1 | 2005 | 13 | 0.090 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2004 | 7 | 0.080 |
Why?
| | Prevalence | 2 | 2016 | 478 | 0.080 |
Why?
| | Blood Transfusion | 1 | 2004 | 62 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2016 | 2644 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 1 | 2004 | 82 | 0.080 |
Why?
| | Depression | 1 | 2008 | 425 | 0.080 |
Why?
| | Young Adult | 3 | 2018 | 1830 | 0.080 |
Why?
| | Infant, Premature | 1 | 2004 | 187 | 0.070 |
Why?
| | Prospective Studies | 1 | 2008 | 1527 | 0.070 |
Why?
| | Gastric Acid | 1 | 2002 | 11 | 0.070 |
Why?
| | Liver Diseases | 1 | 2002 | 38 | 0.070 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2002 | 180 | 0.070 |
Why?
| | Permeability | 1 | 2002 | 136 | 0.070 |
Why?
| | Acute Disease | 1 | 2002 | 256 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2016 | 1117 | 0.060 |
Why?
| | Disease Susceptibility | 1 | 2018 | 70 | 0.050 |
Why?
| | Biodiversity | 1 | 2018 | 28 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2008 | 4375 | 0.050 |
Why?
| | South Africa | 1 | 2017 | 7 | 0.050 |
Why?
| | Syndrome | 1 | 2016 | 107 | 0.050 |
Why?
| | Continental Population Groups | 1 | 2017 | 93 | 0.050 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 48 | 0.050 |
Why?
| | Pilot Projects | 1 | 2017 | 383 | 0.040 |
Why?
| | Population Surveillance | 1 | 2016 | 117 | 0.040 |
Why?
| | Aspirin | 1 | 2016 | 69 | 0.040 |
Why?
| | Exhalation | 1 | 2014 | 2 | 0.040 |
Why?
| | Spirometry | 1 | 2014 | 7 | 0.040 |
Why?
| | Phenotype | 1 | 2016 | 320 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2014 | 35 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2014 | 84 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2014 | 102 | 0.040 |
Why?
| | Blood Cell Count | 1 | 2013 | 21 | 0.040 |
Why?
| | Vincristine | 1 | 2013 | 36 | 0.040 |
Why?
| | Immunoglobulins | 1 | 2013 | 29 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2013 | 57 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 270 | 0.040 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 46 | 0.040 |
Why?
| | Doxorubicin | 1 | 2013 | 71 | 0.040 |
Why?
| | Antigens, CD | 1 | 2013 | 104 | 0.040 |
Why?
| | Prednisone | 1 | 2013 | 72 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2014 | 593 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 317 | 0.030 |
Why?
| | Body Mass Index | 1 | 2014 | 369 | 0.030 |
Why?
| | United States | 1 | 2016 | 2020 | 0.030 |
Why?
| | Basophils | 1 | 2009 | 11 | 0.030 |
Why?
| | Superoxides | 1 | 2009 | 31 | 0.030 |
Why?
| | Blotting, Western | 1 | 2009 | 228 | 0.030 |
Why?
| | Ranitidine | 1 | 2006 | 4 | 0.020 |
Why?
| | Histamine H1 Antagonists, Non-Sedating | 1 | 2006 | 4 | 0.020 |
Why?
| | Cetirizine | 1 | 2006 | 7 | 0.020 |
Why?
| | Duodenum | 1 | 2006 | 11 | 0.020 |
Why?
| | Tryptases | 1 | 2006 | 10 | 0.020 |
Why?
| | Serine Endopeptidases | 1 | 2006 | 19 | 0.020 |
Why?
| | Cell Count | 1 | 2006 | 117 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2006 | 250 | 0.020 |
Why?
| | Colon | 1 | 2006 | 132 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2006 | 3246 | 0.010 |
Why?
|
|
Tobin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|